Recent advances in probiotics as live biotherapeutics against gastrointestinal diseases

Current Pharmaceutical Design

Volumn 24, Issue 27, 2018, Pages 3162-3171

  Kota, Rohini Krishna ^a   Ambati, Ranga Rao ^a   Aswani Kumar, Y V V ^b   Srirama, Krupanidhi ^a   Reddy, Prakash Narayana ^a  

^a VIGNAN UNIVERSITY   (India)

^b ACHARYA NAGARJUNA UNIVERSITY   (India)

Author keywords

Biotherapeutics; Fecal Microbial Transplants (FMT s); Gastrointestinal diseases; Gut microbiota modulation; Probiotics; Therapy

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN Y; OLIGOSACCHARIDE; ORAL REHYDRATION SOLUTION; PROBIOTIC AGENT;

CAMPYLOBACTER; CLINICAL TRIAL (TOPIC); COLOSTRUM; DIARRHEA; DYSBIOSIS; DYSENTERY; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL DISEASE; GIARDIA; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; SHIGELLA; SUPPLEMENTATION; ANIMAL;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; PROBIOTICS;

EID: 85058491120     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612824666180717105128     Document Type: Review

References (135)

1. MacGill M. What you should know about diarrhea. 2017; Available at: (https://www.medicalnewstoday.com/articles/158634.php)
2. Roman C, Solh T, Broadhurst M. Infectious Diarrhea. Physician Assistant Clinics 2017; 2(2): 229-245.
3. Liu L, Johnson HL, Sousens S, et al. Global, regional, and national causes of child mortality: an updated systemic analysis for 2010 with time trends since 2000. Lancet 2012; 379(9832): 2151-61.
4. Garthright WE, Archer DL, Kvenberg JE. Estimates of incidence and costs of intestinal infectious diseases in the United States. Public Health Rep 1988; 103(2): 107-15.
5. Taylor EV, Herman KM, Ailes EC, et al. Common source outbreaks of Campylobacter infection in the USA, 1997-2008. Epidemiol Infect 2013; 141(5): 987-99.
6. Blaser MJ, Engberg J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. In Campylobacter, Third Edition (pp. 99-121). American Society of Microbiology 2008.
7. Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis 1984; 6(3): 345-56.
8. Gill CJ, Keene WE, Mohle-Boetani JC, et al. Alfalfa seed decontamination in a Salmonella outbreak. Emerg Infect Dis 2003; 9(4): 474-9.
9. Hennessy TW, Hedberg CW, Slutsker L, et al. A national outbreak of Salmonella enteritidis infections from ice cream. New Engl J Med 1996; 334(20): 1281-1286.
10. Kimura AC, Reddy V, Marcus R, et al. Emerging Infections Program FoodNet Working Group. Chicken consumption is a newly identified risk factor for sporadic Salmonella enterica serotype Enteritidis infections in the United States: a case-control study in FoodNet sites. Clin Infect Dis 2004; 38(Supplement 3): S244-S252.
11. Ao TT, Feasey NA, Gordon MA, et al. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg Infect Dis 2015; 21(6): 941-9.
12. Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitits complicating sickle cell disease. Pediatrics 1998; 101(2): 296-7.
13. Acheson D, Hohmann EL. Nontyphoidal salmenollosis. Clin Infect Dis 2001; 32(2): 263-9.
14. Hatta M, Smits HL. Detection of Salmonella typhi by nested po-lymerase chain reaction in blood, urine, and stool samples. Am J Trop Med Hyg 2007; 76(1): 139-43.
15. Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin resistant Campylobacter infection. J Infect Dis 2004; 190(6): 1150-7.
16. Jacobs BC, van Belkum A, Endtz HP. Guillain-Barre´ syndrome and campylobacter infection. In: Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter. 3rd edition. Washington, DC: ASM Press; Chapter 13 2008; p: 245-62.
17. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guil-lain-Barre´ syndrome. Clin Microbiol Rev 1998; 11(3): 555.
18. Kalra V, Chaudhry R, Dua T, et al. Association of Campylobacter jejuni infection with childhood Guillain-Barre´ syndrome: a case study. J Child Neurol 2009; 24(6): 664-8.
19. Pope JE, Krizova A, Garg AX, et al. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 2007; 117: 237-57.
20. Sanders JW, Frenck RW, Putnam SD, et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler’sdiarrhea in United States military personnel in Turkey. Clin Infect Dis 2007; 45(3): 294-301.
21. Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3 day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44(3): 338-46.
22. Majowicz SE, Musto J, Scallon E, et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 2010; 50(6): 882-9.
23. Feng Y, Xiao L. Zoonotic potential and molecular epidemiology of Giardia species and giardiasis. Clin Microbiol Rev 2011; 24(1): 110-40.
24. Baldursson S, Karanis P. Waterborne transmission of protozoan parasites: review of worldwide outbreaks-an update 2004-2010. Water Res 2011; 45: 6603-14.
25. Painter JE, Gargano JW, Collier SA, et al. Giardiasis surveillance-United States, 2011-2012. MMWR SurveillSumm 2015; 64(3): 15-25.
26. Shaw PK, Brodsky RE, Lyman DO, et al. A communitywide outbreak of giardiasis with evidence of transmission by a municipal water supply. Ann Intern Med 1977; 87(4): 426-32.
27. Mintz ED, Hudson-Wragg M, Mshar P, et al. Foodborne giardiasis in a corporate office setting. J Infect Dis 1993; 167(1): 250-3.
28. Quick R, Paugh K, Addiss D, et al. Restaurant-associated outbreak of giardiasis. J Infect Dis 1992; 166(3): 673-6.
29. Esch KJ, Petersen CA. Transmission and epidemiology of zoonotic protozoal disease of companion animals. Clin Microbiol Rev 2013; 26(1): 58-85.
30. Hill DR. Giardiasis: Issues in diagnosis and management. Infect Dis Clin North Am 1993; 7(3): 503-25.
31. Loftus B, Anderson I, Davies R, Alsmark UCM, Samuelson J, Amedeo, P. The genome of the protist parasite Entamoeba histo-lytica. Nature 2005; 433(7028): 865-8.
32. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42(12): 1118-25.
33. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genet 2011; 43(3): 246-52.
34. Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 2008; 14(7): 968-976.
35. Clamp SE, Myren J, Bouchier IA, Watkinson G, de Dombal FT. Diagnosis of inflammatory bowel disease: an international multicentre scoring system. Br Med J (Clin Res Ed) 1982; 284(6309): 91-95.
36. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
37. Orholm M, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-88.
38. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn’s disease in an unselected population of monozy-gotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-996.
39. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opinion on Investigational Drugs 2018; 27(3): 219-224.
40. Alam NH, Ashraf H, Kamruzzaman M, et al. Efficacy of partially hydrolyzed guar gum (PHGG) supplemented modified oral rehydra-tion solution in the treatment of severely malnourished children with watery diarrhea: a randomised double-blind controlled trial. J Health Popul Nutr 2015; 34: 1-3.
41. Kunz C, Meyer C, Collado MC, et al. Influence of gestational age, secretor, and Lewis blood group status on the oligosaccharide content of human milk. J Pediatr Gastroenterol Nutr 2017; 64: 789-798.
42. Kumaran T, Thirumalaikumar E, Lelin C, et al. Physicochemical properties of anti-Vibrio harveyi egg yolk antibody (IgY) and its immunological influence in Indian white shrimp Fenneropenaeus indicus. Fish Shellfish Immun 2018; 74: 349-362
43. Hong KS, Ki MR, Ullah HA, et al. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice. Vaccine 2018; 36(3): 371-380.
44. Gartner LM, Morton J, Lawrence RA, et al. Breastfeeding and the use of human milk. Pediatrics 2005; 115: 496-506.
45. Owen CG, Whincup PH, Odoki K, et al. Infant feeding and blood cholesterol: a study in adolescents and a systematic review. Pediatrics 2002; 110: 597-608.
46. Mellander O. The physiological importance of the casein phos-phopeptide calcium salts. II. Peroral calcium dosage of infants. Acta Soc Med Ups 1950; 55: 247-55.
47. FitzGerald RJ. Potential uses of caseinophosphopeptides. Int Dairy J 1998; 8: 451-7.
48. Naito H, Kawakami A, Imamura T. In vivo formation of phos-phopeptide with calcium-binding property in the small intestinal tract of the rat fed on casein. Agric Biol Chem 1972; 36: 409-15.
49. Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol 2017; 2(5): 17057.
50. Sun X, Fiala JL, Lowery D. Patent watch: modulating the human microbiome with live biotherapeutic products: intellectual property landscape. Nat Rev Drug Discov 2006; 15: 224-225.
51. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biol. Targets Ther 2011; 5: 71-86.
52. Young VB. The intestinal microbiota in health and disease. Curr Opin Gastroenterol 2012; 28(1): 63-9.
53. Walter J, Maldonado-Gómez MX, Martínez I. To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes. Curr Opin Biotechnol 2018; 49: 129-139.
54. Senghor B, Sokhna C, Ruimy R, Lagier JC. Gut microbiota diversity according to dietary habits and geographical provenance. Hum Microbiom J 2018; 7: 1-9.
55. Savage DC.Microbial ecology of the gastrointestinal tract.Annu Rev Microbiol 1977; 31:107-133.
56. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature.2010; 464: 59-65.
57. Eberl G. A new vision of immunity: homeostasis of the superorgan-ism. Mucosal Immunol 2010; 450-460.
58. Moschen AR, Wieser V, Tilg H. Dietary factors: major regulators of the gut's microbiota. Gut Liver 2012; 6(4), 411.
59. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. P Natl Acad Sci USA 2010; 107(26), 11971-5.
60. Rodríguez JM, Murphy K, Stanton C, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 2015; 26(10): 26050.
61. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutual-ism in the human intestine. Science 2005; 307: 1915-20.
62. Quigley EM. Gut bacteria in health and disease. J Gastroenterol Hepatol 2013; 9.9: 560-9.
63. Szablewski L. Human gut microbiota in health and Alzheimer’s disease. J Alzheimers Dis 2018; 62(2): 549-560.
64. Wong JM, de Souza R, Kendall CW, et al. Colonic health: Fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-43.
65. Lankelma JM, Nieuwdorp M, de Vos WM, Wiersinga WJ. The gut microbiota in internal medicine: implications for health and disease. Neth J Med 2015; 73(73): 61-8.
66. Brahe LK, Astrup A, Larsen IH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev2013; 14: 950-959.
67. Samuel BS, Shaito A, Motoike T, et al. Effects of gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 2008; 105: 16767-72.
68. Sonnenburg JL. Backhed F Diet-microbiota interactions as mediators of human metabolism. Nature 2016; 235: 56-64.
69. Schilderink R, Verseijden C, de Jonge WJ. Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis. Front Immunol 2013; 4: 226.
70. Pokrzywnicka P, Gumprecht J. Intestinal microbiota and its relationship with diabetes and obesity. Clin Diabetol 2016; 5: 164-172.
71. Atarashi K, Tanoue T, Shima, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Nature 2011; 331: 337-341.
72. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80(Suppl 1): S147-S171.
73. Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defense against pneumococcal pneumonia. Gut 2016; 65: 575-583.
74. Midtvedt T.Microbial bile acid transformation. Am J ClinNutr 1974; 27: 1341-7.
75. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 2013; 6(4): 295-308.
76. Blaut M, Collins MD, Welling GW, Dore J, Van LJ, de Vos W. Molecular biological methods for studying the gut microbiota: The EU human gut flora project. Br J Nutr 2002; 87 Suppl 2: S203-211.
77. McCartney AL. Application of molecular biological methods for studying probiotics and the gut flora. Br J Nutr 2002; 88 (Suppl 1): S29-S37.
78. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
79. Hernández JM. Gut Microbiota and Health: A Review. EC Gastroenterology and Digestive System 2017; 2: 411-425.
80. Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics—Advances and challenges. Adv Drug Deliv Rev 2016; 105: 44-54.
81. Angelakis E, Bastelica D, Amara AB, et al. An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism on mice. Microb Pathog 2012; 52: 61-68.
82. Jacobsen CN, Nielsen VR, Hayford AE, Møller, et al. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 1999; 65(11): 4949-56.
83. Li SS, Zhu A, Benes V. et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016; 352(6285): 586-9.
84. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011; 65: 411-429.
85. Costello EK, Stagaman K, Dethlefsen L, et al. The application of ecological theory toward an understanding of the human microbiome. Science 2012; 336(6086): 1255-1262.
86. Chase JM, Leibold MA. Ecological niches: linking classical and contemporary approaches.2003; University of Chicago Press.
87. Maldonado-Gómez MX, Martínez I, Bottacini F, et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 2016; 20(4): 515-526.
88. Hamady ZZ, Scott N, Farrar MD, et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroidesovatus. Gut 2010; 59: 461-9.
89. Hamady ZZ, Scott N, Farrar MD, et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan. Inflamm Bowel Dis 2010; 17(9): 1925-35.
90. Motta JP, Bermúdez-Humarán LG, Deraison C, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4(158): 158ra144.
91. Robert S, Steidler L. Recombinant Lactococcuslactis can make the difference in antigen-specific immune tolerance induction, the type 1 diabetes case. Microb Cell Fact 2014; 13(Suppl 1): S11.
92. Deng H, Li Z, Tan Y, Guo Z, Liu Y, Wang Y et al. A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages. Sci Rep 2016; 6; 29401.
93. Woo TD, Oka K, Takahashi M, et al. Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain. J Med Microbiol 2011; 60: 1617-1625.
94. Isa K, Oka K, Beauchamp N, et al. Safety assessment of the Clostridium butyricum MIYAIRI 588(R) probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo. Hum Exp Toxicol 2016; 35: 818-832.
95. Rossi O, Van Berkel LA, Chain F, et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep 2016; 6: 18507.
96. Song H, Yoo Y, Hwang J, et al. Faecalibacterium prausnitzii sub-species-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol 2016; 137: 852-860.
97. Feng JR, Wang F, Qiu X, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. ‎Eur J Clin 2017; 73(10): 1199-1208.
98. Sharif A, Kashani HH, Nasri E, et al. The role of probiotics in the treatment of dysentery: a randomized double-blind clinical trial. Probiotics and antimicrobial proteins 2017; 9(4): 380-385.
99. Shin SP, Choi YM, Kim WH, et al. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. JCBN 2018; 62(2): 179-186.
100. Sun YY, Li M, Li YY, et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep 2018; 8(1): 2964.
101. Sameshima T, Magome C, Takeshita K, Arihara K, Itoh M, Kondo Y. Effect of intestinal Lactobacillus starter cultures on the behaviour of Staphylococcus aureus in fermented sausage. Int J Food Microbiol 1998; 41(1): 1-7.
102. Charlier C, Cretenet M, Even S, Le Loir Y. Interactions between Staphylococcus aureus and lactic acid bacteria: an old story with new perspectives. Int J Food Microbiol 2009; 131(1): 30-39.
103. Jayashree S, Karthikeyan R, Nithyalakshmi S, Ranjani J, Gunasekaran P, Rajendhran J. Anti-adhesion Property of the Potential Probiotic Strain Lactobacillus fermentum 8711 Against Methi-cillin-Resistant Staphylococcus aureus (MRSA). Front Microbiol 2018; 9: 411.
104. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371(9613): 651e9.
105. Raoult D. Obesity pandemics and the modification of digestive bacterial flora. Eur J Clin Microbiol Infect Dis 2008; 27(8): 631-634.
106. Bermúdez-Humarán, Luis G, et al. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011; 10(Suppl 1): S4.
107. Singh B, Mal G, Marotta F. Designer probiotics: paving the way to living therapeutics. Trends Biotechnol 2017; 35(8): 679-682.
108. Shigemori S, Shimosato T. Applications of genetically modified immunobiotics with high immunoregulatory capacity for treatment of inflammatory bowel diseases. Front Immunol 2017; 8: 22.
109. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with trans-genic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4(6): 754-759.
110. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcuslactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21(7): 785-9.
111. Hopkins DW, Chudek JA, Bignell DE, et al. Application of C NMR to investigate the transformations and biodegradation of organic materials by wood-and soil-feeding termites, and a coprophagous litter-dwelling dipteran larva. Biodegradation 1998; 9: 423-31.
112. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-9.
113. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42(Suppl 1): S5-12.
114. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010; 8: 471-3.
115. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9.
116. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am GeriatrSoc 2013; 61: 1394-8.
117. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013; 78: 240-9.
118. Dietrich M, Fliedner TM. Gnotobiotic care of patients with immunologic deficiency diseases. Transplant Proc 1973; 5: 1271-7.
119. Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microb 2013; 4(2): 125-35.
120. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42-8.
121. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile associated diarrhea. J Infect Dis 2008; 197: 435-8.
122. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile associated diarrhea. J Clin Gastroenterol 2010; 44: 354-60.
123. Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'Re-POOPulating' the gut. Microbiome 2013; 1: 1-12.
124. Banerjee P, Merkel GJ, Bhunia AK. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009; 1(1): 8.
125. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008; 190: 2505-12.
126. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile sporegermination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 2010; 192: 4983-90.
127. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010; 28: 965-9.
128. Miller JM, Astles R, Baszler T, et al. Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel. MMWR Surveill Summ 2012; 61 Suppl: 1-102.
129. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
130. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterol 2013; 145(5): 946-953.
131. Allen-Vercoe E, Reid G, Viner N, et al. A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 2012; 26: 457-62.
132. Reich PB, Tilman D, Isbell F, et al. Impacts of biodiversity loss escalate through time as redundancy fades. Science 2012; 336: 589-92.
133. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336: 489-93.
134. Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488: 621-6.
135. Diaz Heijtz R, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047-52.